Cephalon Loses Bid For Quick Win In Marketing Suit
Cephalon Inc. lost a summary judgment bid Wednesday in a Pennsylvania class action claiming the company marketed the cancer pain management drug Actiq for off-label uses and caused third-party payors to...To view the full article, register now.
Already a subscriber? Click here to view full article